Frequently Asked Questions

503A pharmacies prepare patient-specific compounded medications based on individual prescriptions. 503B facilities are FDA-registered outsourcing facilities that can produce larger batches under cGMP standards without a patient-specific prescription. MedClinic Partners provides licensed clinics and pharmacies access to both pathways through a single portal.

We onboard licensed providers in all 50 states. Fulfillment depends on the producing partner's state licenses and the SKU's lawful pathway. We do not operate as the pharmacy.

Licensed providers submit their NPI through the portal. Verification runs against the live CMS registry and is typically completed in under 60 seconds. Most providers can place their first order the same day. There are no portal fees or minimum order requirements.

Yes. Access is restricted to licensed medical providers and 503A pharmacies with a valid NPI (or equivalent pharmacy credentials). The portal is not available to the general public.

Licensed physicians, nurse practitioners, physician assistants, medical clinics, med spas, and 503A pharmacies with valid credentials.

You enter your NPI number. Our system verifies it instantly against the CMS National Plan and Provider Enumeration System. Once verified, portal access is granted immediately.

No. There are no portal fees, no setup charges, and no minimum order requirements.

Most licensed providers complete verification and place their first order the same day.

We introduce licensed clinics to 503A patient-specific compounding where it remains lawful after the FDA shortage-list changes. 503B bulk copies of commercially available semaglutide or tirzepatide are restricted and are not offered as office stock. Research-use-only peptides are a separate catalog and are not for clinical administration. See our 503A vs 503B vs RUO comparison.

Beyond-use dates are assigned by the compounding facility based on USP <797>/<795> category and stability data for that specific preparation. We do not publish a blanket BUD.

Compounded medications are not FDA-approved in the same way as commercially manufactured drug products. They are prepared by licensed 503A or 503B facilities under applicable federal and state regulations. We work only with compliant facilities and maintain continuous regulatory monitoring.

High-purity USA-manufactured research peptides including BPC-157, TB-500, CJC-1295/Ipamorelin, PT-141, Sermorelin, Epithalon, and others. Availability is limited to approved providers.

The research peptides available through the portal are designated for research use only (RUO) unless otherwise specified under a compliant clinical or compounding pathway.

All temperature-sensitive products ship overnight via FedEx or UPS with validated cold-chain packaging to protect product integrity.

Our team includes attorneys with extensive pharmaceutical litigation and regulatory experience. We continuously monitor USP <795>/<797>/<800>, FDA 503A/503B guidance, and state board requirements and provide proactive compliance support.